Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5324208 | 0.86 | ALDH1A1 (0.67) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18171802 | 0.84 | SMN1; SMN2 (0.61) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18171828 | 0.80 | SMN1; SMN2 (0.63) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3581111 | 0.79 | APEX1 (0.76) | ALDH1A1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL12611486 | 0.77 | GLA (0.62) | ALDH1A1LMNASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL3571941 | 0.77 | ALDH1A1 (0.56) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7734714 | 0.75 | ALDH1A1 (0.81) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5323858 | 0.75 | CYP1A2 (0.51) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5288497 | 0.75 | LMNA (0.52) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24405821 | 0.75 | RAB9A (0.68) | LMNAKMT2AL3MBTL1POLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | ALDH1A1 2972/4885LMNA 3704/4885MEN1 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.